BioArctic says real-world LEADER study shows 82.5% of Leqembi patients remain stable or improve over 17 months

  • BioArctic flagged interim real-world LEADER study results showing 82.5% of early Alzheimer’s patients on Leqembi stayed stable or improved.
  • Among 427 evaluable patients, 75.9% remained stable over about 17 months; 6.6% improved from mild dementia to MCI.
  • Nearly 87% stayed on treatment; findings were reported as consistent across sex, race, ethnicity, APOE genotype.
  • Safety profile matched the US label; ARIA occurred in 12.3% overall, mostly asymptomatic, mild.
  • No new ARIA-E events or major brain bleeds were reported during once-every-four-weeks IV maintenance dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202607141115BITN____UKPR__EN_20260714-BIT-8705-0) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.